The recent FDA approval for the BCL2-specific inhibitor Venclexta (ABT-199/GDC-0199) in chronic lymphocytic leukemia (CLL) provided clinical proof of concept for such approaches. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.